Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Candesartan + amlodipine is a fixed-dose combination of two antihypertensive agents used to treat high blood pressure (hypertension). Candesartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the type-1 angiotensin II receptor (AT1), thereby preventing vasoconstriction and aldosterone secretion, which results in lowered blood pressure[4][6]. Amlodipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to relaxation of blood vessels and reduced cardiac workload[2][3]. The combination provides complementary mechanisms for lowering blood pressure and may be used when monotherapy with either agent does not achieve adequate control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on candesartan + amlodipine.